EE165 Cost-Effectiveness Analysis of Liposomal Formulation of Daunorubicin and Cytarabine (CPX-351) for the Treatment of Adult Patients With Newly Diagnosed Therapy-Related AML or AML With Myelodysplasia-Related Changes in Greece

Authors :: MA Loupas
K Lioliou
G Gourzoulidis
Z Vostitsanou
A Giannakopoulou
G Kourlaba
Source :: Value in Health. 25:S85
Publication Year :: 2022
Publisher :: Elsevier BV, 2022.

Subjects :: Health Policy
Public Health, Environmental and Occupational Health

Full Text Access

Tools